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Background: Osteopetrosis is a rare genetic disorder characterized by increased bone density due to a defective
osteoclast’s bone resorption. Three clinical forms can be identified based on severity, age of onset and inheritance: the
dominant benign form (ADO), the intermediate form (IRO) and the recessive severe form (ARO). Several genes have been
involved in the pathogenesis of these different types of osteopetrosis. Many experimental evidences point out on a
specific role for CLCN7, the gene encoding the chloride channel protein subunit alfa and for TCIRG1, the gene encoding
an osteoclast specific subunit of the vacuolar proton pump. Mutations in CLCN7 gene have been associated to the
complete spectrum of osteopetrosis ranging from ARO to IRO and even to ADO type II. On the other hand, mutations
in TCIRG1 gene account for more than 50% of cases of ARO. It is then evident that the malignant osteopetrosis is
characterized by a great molecular and clinical heterogeneity often making the final diagnosis difficult to achieve.
Methods: We performed a complete clinical, biochemical and molecular analysis by PCR and direct sequencing, of a
novel case of osteopetrosis with inconsistent clinical phenotype.
Results: The patient, who cannot be ascribed to any of the ADO, ARO or IRO groups, carried two novel mutations in
compound heterozygosis in the CLCN7 gene. The first was the missense mutation c. 948C > T on exon 10 that produces
an Arg to Cys change, while the second was the IVS11 + 5G > A splicing mutation that resides on the donor splice site of
intron 11 and distrupts the canonical splice site.
Conclusion: Our data
a) Demonstrate that the unusual clinical presentation observed in our patient with a mild clinical onset evolving
towards a more serious clinical picture, is associated to two novel mutations on CLCN7 gene.
b) Support the already described clinical and molecular heterogeneity of the malignant osteopetrosis
c) Suggest that, performing a molecular diagnosis of osteopetrosis with inconsistent clinical presentation these two
novel mutations have to be first considered.
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Osteopetrosis is described as a heterogeneous group of
diseases [1] related to defective bone resorption [2,3]. In
the maintenance of this function, the regulation of pH in
specific intracellular and extracellular compartments of
osteoclasts is critical [4]. Beside the proton production,* Correspondence: roberto.miniero@unicz.it
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H+-ATPase responsible for the acidification of the resorp-
tion compartment [5]. In this context a specific role both
for the CLCN7 and TCIRGI genes has recently been
demonstrated [6]. CLCN7 (Gene Bank NG_007567) is a
member of the mammalian CLC gene family. It is
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encoded protein clc7 (UniProt P51798) is localized in
the ruffled border and it is involved in the acidification
process. In humans, mutations in the CLCN7 gene give
rise to a complete spectrum of malignant osteopetrotic
phenotypes [7]. The protein encoded by the TCIRG1
gene, Tcrg1, (Gene Bank NG_007898,Uni Prot Q13488)
is a subunit of the vacuolar proton pump involved in
the process of extracellular acidification. This protein
was initially identified in mice as produced by an
osteoclast-specific gene, whose targeted deletion causes
osteoclast-rich osteopetrosis [8]. In humans TCIRG1 is
the most common affected gene accounting for about
50% of the malignant osteopetrotic phenotypes.
Clinically osteopetrosis is classified in three different
forms: malignant infantile form with poor prognosis and
autosomal recessive inheritance (ARO), benign/adult osteo-
petrosis with autosomal dominant inheritance (ADO)
and autosomal recessive intermediate form (IRO) with
clinical manifestation similar to the malignant form but
with a lower incidence. Despite of this classification a
clear genotype-phenotype correlation is not evident in
the patients so far described. We report on the clinical
and molecular characterization of a novel case of malig-
nant osteopetrosis that for presentation and progression is
not classifiable in any of the above mentioned clinical
groups and demonstrate that the inconsistent phenotype
in our patient is related to the presence of two novel
mutations in the CLCN7 gene.
Case report
The patient was a 16 months girl, born from non con-
sanguineous parents referred to our department for a
suspect of osteopetrosis. At the admission, the radio-
logical investigation showed a small left wrist fracture
due to trivial (minor) trauma, a diffuse increase in the
bone density with obliteration of the marrow cavity and
evidence of a bone appearance in the small bones of
the hands and feet. The past medical history of the
patient revealed she was hospitalized in the first month of
life for fall to thrive, hepatosplenomegaly with increased
sereum levels of lactic deidrogenase (LDH), creatin
phosphokinase (CPK) alkaline phosphatase (ALP) and
aminotransferases.
The patient showed a weight of 8,6Kg (5^-10^ per-
centile), a height of 76, 5 cm (25^ percentile) and a head
circumference of 48 cm (<90^ percentile). Moderate
hepatosplenomegaly and delayed dental eruption were
also observed. The fundoscopic examen was negative.
All the laboratory findings were normal except for a
marked increase in the serum level of LDH (1850 UI),
CPK (727 UI) ALP and aminotransferase. The urinary
pH was 5,5. The hemogram was normal. The early onset
of the carbonic anhydrase II deficiency syndrome issometimes characterized by spontaneous fractures with-
out renal acidosis [9]. Therefore based on the clinical
and radiological evidences we evaluated the CAII activity
that was in the normal range (15 U/mgHb) allowing us
to rule out such condition. A blood sample was collected
to perform a molecular study of the main genes involved
in the malignant osteopetrosis.
Eight months later the patient was hospitalized again
because of the worsening of the clinical conditions.
Specifically the patient had a severe growth retardation,
macrocephaly, frontal bossing, faillure of dental eruption,
visual impairment with nystagmus, hemiparesis of left
inferior limb without other cranial nerve’ involvement.
Hepatosplenomegaly was increased.
The laboratory investigation revealed severe normocytic-
normochromic anemia, trombocytopenia, persistent
high levels of LDH, CK and serum acid phosphatase.
Serum calcium was normal. The radiological skeletal
survey confirmed the osteopetrotic picture observed
before (Figure 1). The molecular and genetic evaluation
demonstrated the involvement of CLCN7, one of the
main gene responsible of malignant osteopetrosis. Based
on all of the above described evidences a final diagnosis
of malignant osteopetrosis with atypical onset was
established. Because of the rapid clinical worsening, the
patient underwent to a succesfull allogenic bone mar-
row transplantion (the oldest sister, resulting HLA full
matching, was the donor. Specifically, visual impairment
was completely rescued as well anemia, and trombocy-
topenia,. A normalization of LDH, CK and serum acid
phosphatase levels was observed.Methods
Sample blood collection
Informed consent was obtained from all subjects and/or
their parents. All the procedures described above were
performed for diagnostic purpose.
Blood specimens were collected by venipuncture in
heparinized test tubes. After collection the specimens
were diluited 1:100 with distilled water and then stored
to -20°C until the hemoglobin and CAs were assayed.Hemoglobin assay
For the evaluation of Hb levels a spectrophotometric assay
was used.
Briefly, 0.2 ml of 1:100 diluted blood were added to
0.8 ml of ammonium hydroxide solution 0.006 N. The
optical density at 576 nm (OD 576) was read on a
Beckmann DU 60 spectrophotometer using as blank a
0.2 ml of distilled water. The hemoglobin levels (mg/ml)
were calculated by the formula: mg Hb/ml =OD576 ×
500/0.912 [9].
AB
Figure 1 Radiographic analysis of a case with CLCN7 dependent
OP. A) Skull view showing thickening of the inner and outer cortical
tables. B) Chest showing generalised osteosclerosis in the thoracic cage.
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The CAI plus CAII (Catot) and CA II specific activities were
evaluated according to the “Fish Tank Assay” method [9].
Briefly: for each patient two tubes with phenol red
solution as indicator without or with 0.125 sodium iod-
ide as inhibitor of CAI activity were prepared. The tubes
were left on ice at 4°C for one hour. Carbonic anhidride
(CO2) was bubbled in all tubes at 600 ml/min for 60 sec-
onds, and then 100 μl of water for uncatalyzed reaction
(Tuc) or a 1:100 diluition of sample blood for thecatalyzed reaction (Tc), 2 ml of a barbital buffer (diethyl-
barbituric acid, ) ice cold pH 7.8 were added to start
the reaction. The time required to reach the end point
at pH 7.2 after the addition of barbital buffer, was mea-
sured using a standard phenol red solution pH 7.2 as
indicator dye. The CAtot (CAI plus CAII activities) and
CAII specific activities were calculated by the expression:
Tuc-Tc/Tc X diluition factor (where Tuc = Time of unca-
talyzed reaction, Tc = Time of catalyzed reaction). Results
for CA levels were expressed in units of CA per mg of Hb.
Polymerase chain reaction
Blood samples for the molecular analysis, were drawn by
venipuncture in EDTA pretreated tubes, After DNA ex-
traction, all the exons and the boundary intronic regions
were individually amplified by Polymerase Chain reac-
tion (PCR) using nucleotide primer pairs designed on
the basis of the published CLCN7 and TCIRG1 gene se-
quences. PCR amplification was performed using 100 ng
of genomic DNA in a 30 μl volume with 250 μM final
concentration of dNTPs, a 1.5 mM final concentration
of MgCl2, 10 pM of of each primer and 1U Taq DNA
polymerase. After heating 94°C for 3 min, 30 cycles were
performed at 94°C for 1 min, 55°C for 1 min and 72°C
for 1 min before a final step of 72°C for 10 min. Each
PCR product (15 μl) was electrophoresed on 1.8% agar-
ose and visualized using ethidium bromide staining.
Direct sequencing
The PCR products were purified by PCR Purification Kit
(Roche) and sequenced by dideossi chain terminator reac-
tion using a Big-Dye terminator kit according to the man-
ufacturer’s instructions (A.P.Biosystem) and run on 310
ABI Prism Analyzer The sequences were then analyzed
using a FASTA and ASSEMBLING software (A.P. Biosys-
tem). The point mutations identified were confirmed by
sequencing the opposite strands and comparing with the
relative wild type sequences published in gene data bank
(CLCN7 Ref NG_007567; TCIRG1 Ref NG_007878. The
putative structural consequences of missense mutations
were predicted based on the sequences analysis and mul-
tiple sequence alignment information.
Bioinformatic analysis
The effects of the putative novel splicing mutation (de-
fined as never described on HGMD site www.hgmd.cf.ac.
uk/ac/index.php or published in Pubmed) were studied in
silico by using the ASSEDA software (http://splice.uwo.ca/
cgi-bin/protected/display.cgi?forweb_sis).
Results and discussion
Carbonic anhydrase II assay
We ruled out a possible osteopetrosis due to a carbonic
anhydrase II deficiency by performing the residual enzyme
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the human Carbonic anhydrase isoenzyme II activity
already published, [9] we found in our patient a value of
15 U/mg of Hb in the normal range. This data allow us to
exclude the Carbonic anhydrase II deficiency syndrome.
Molecular analysis
Based on the clinical and biochemical findings we decided
to perform a molecular analysis of the CLCN7 and TCIRG1
genes primarily responsible for the different forms of
malignant osteopetrosis. Figure 2 shows the results ofA B
C D
c.948C>T ( p R280C)
24359+5bp G>A   (Ivs11+5G>A)
Figure 2 Novel Mutations on CLCN7 gene in a case of OP with inconsis
on Exon 10 of CLCN7 gene. B) The c.948C > T produces a change of Arg 2
transmembrane idrofobic domains. C) Electrophoregram showing the 23459
site of intron 11. D) Asseda bioinformatic analysis of the effect of the Ivs11 + 5
of 4.1 for wild type to 0.9 for the mutant with a predicted folding change of -
leading to the skipping of the Exon 12 using an alternative donor splice site wthe CLCN7 gene sequencing. On the exon 10 of the
CLCN7 gene a transition C/T at codon 948 (c948C > T)
was found. A second transition G >A is evident 5 bp after
the end of exon11 on the donor splice site of intron 11
(IVS11 + 5G >A ). The molecular analysis of the patient’s
parents demonstrate that the c948C > T mutation was
maternal while the IVS11 + 5G >A was inherited from the
father (data not shown) The in silico study based on
sequences analysis and multiple sequence alignment infor-
mation (http://www.ebi.ac.uk/) clearly indicate that the
c948C > T transition on Exon 10 of CLCN7 gene producestent phenotype. A) Electrophoregram showing the c.948C > T transition
80 to Cys (R280C) on the cytosolic loop between the 5th and 6th alfa
+ 5 bp G > A transition (Ivs11 + 5 bp G > A) located on the donor splice
bp G > A transition: the Ri score, drops down from the highest values
9.1 According to this evaluation an abberrant splicing could take place
ith a calculated Ri of 3.46.
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the 5th and 6th alfa transmembrane hydrophobic domains.
Based on the amminoacid changed (a polar positive Arg
with a more reactive Cys) and on the involved domain, it is
possible to hypothesize that this mutation can have some
significant structural consequences. The ASSEDA software
analysis performed on the second mutation on CLCN7
gene, clearly demonstrates that the IVS11 + 5G >A transi-
tion resides on the donor splice site of intron 11 gene and
affects the donor splice site. In fact, the Ri score, defined as
the probability of using the involved sequence, after a base
change, as canonical donor splice site, calculated according
to Roca et al [10] drops down from the highest values of
4.1 for wild type to 0.9 for the mutant with a predicted
folding change of -9.1(data not sown) According to this
evaluation a defective splicing could take place leading to
the skipping of the Exon 12 using an alternative donor
splice site with a calculated Ri of 3.46. Only the well known
c166C >T (R56W) polymorphism was found on TCIRG1.
None of the above described novel sequence variations
was found in 100 healthy unrelated controls, ruling out
the possibility of a population polymorphism. Taken
together this data suggest that both the mutations on
CLCN7 could have a significant functional impact on
the resulting protein.
Conclusion
Osteopetrosis is a rare genetic disorder characterized by
increased bone density due to a defective osteoclast’s bone
resorption. Three main forms can be identified based
on severity, age of onset and inheritance: the dominant
benign form (ADO) that is further divided in two sub-
groups ADO I and ADO II (termed also Albers-Schonberg
disease), the intermediate form (IRO) and the recessive
severe form (ARO). Mutation in several genes have
been associated with the disease but a comprehensive
classification based on the molecular findings is not still
available and the relationship between genotype and
phenotype remains elusive.
ADO is usually diagnosed in adolescence or in adult-
hood. Finding may include fracture due to minor trauma,
osteomyelitis of the mandible or septic osteitis or osteo-
arthritis. Systemic symptoms are absent. Life expectancy is
usually normal.
IRO form is characterized by intermediate severity
between ADO and ARO. The onset is in the childhood
and clinical findings may include spontaneous fracture
for minor trauma. Mild anemia and moderate visual
impairment secondary to optic nerve compression may
be observed. Life expectancy is good.
Affected children with ARO usually present with severe
disease within the first year of life. Most important symp-
toms include faillure to thrive, severe anemia or pancy-
topenia, recurrent infections, gross hepatosplenomegaly,abnormal craniofacial appearance, frontal bossing, com-
pression of cranial nerves with blindness. Bone radio-
graphs show sclerotic bone changes with a sandwich
appearance of the vertebrae and “ bone-within bone” fea-
tures, sclerosis of the skull base. The disease is fatal and
only bone marrow transplantation may be effective.
Clinically our patient may not be classified neither as
ARO, because the onset was delayed to the second year
of life even though the severity of the disease was very
suggestive, nor as IRO, because there was no match both
for age of onset and severity. Moreover the ADO form
was easily ruled out because the disease was not auto-
somal dominant with onset and symptoms not well
matching with this classification. Based on the clinical,
genetic and molecular findings our patient might repre-
sent a subtype of ARO form with late onset. We don’t
know if the slow clinical progression we observed is
related to the novel mutations found on CLCN7. Experi-
ments are in progress to assess the functional effects of
both mutations above described, with a main focus on
the splicing defect. With this work we contribute to the
molecular dissection of the CLCN7 deficient ARO and
provide new insights into the molecular bases of the dis-
ease which can be exploited for the molecular diagnosis
of malignant osteopetrosis with an inconsistent clinical
history and a not clear phenotype.
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